Want to see VNRX full AI Analyst Report?
VNRX Stock Chart & Stats
$0.85
-$0.03(-3.26%)
At close: 4:00 PM EDT
$0.85
-$0.03(-3.26%)
Day’s Range― - ―
52-Week Range$0.60 - $15.12
Previous CloseN/A
Volume397.74K
Average Volume (3M)19.46M
Market Cap
$8.05M
Enterprise Value$35.02
Total Cash (Recent Filing)$2.79M
Total Debt (Recent Filing)$1.77M
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Nov 12, 2026EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.87
Shares Outstanding12,044,339
10 Day Avg. Volume55,156,196
30 Day Avg. Volume19,458,360
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-0.80
Price to Sales (P/S)15.80
P/FCF Ratio-1.38
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$14.00Price Target Upside1547.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.24
Revenue Forecast (FY)$2.21M
Bulls Say, Bears Say
Bulls Say
Revenue Growth With Solid Gross MarginsSustained double-digit revenue growth and a ~60% gross margin indicate the company’s products exhibit attractive unit economics. If commercialization and reimbursement progress continue, these margins support scalable gross-profit expansion as volumes rise, aiding long-term margin sustainability.
Proprietary Scientific And Product MilestonesMultiple platform advances (high-purity Capture-Seq, validated Nu.Q Vet automation and feline assay, finger‑prick POC detection) reflect durable IP and product differentiation. These technical milestones create credible pathways to commercial adoption across human, veterinary and point-of-care markets.
Reduced Debt And Governance/capital ActionsMaterial reduction in reported debt and recent share‑based repayments lower near‑term cash interest and maturity pressures. Combined with shareholder-approved governance/capital changes, this provides incremental financing flexibility and reduces acute rollover risk versus prior periods.
Bears Say
Large And Persistent Cash BurnOngoing multi‑million negative operating and free cash flow means the business lacks self‑funding capacity and will repeatedly need external capital to sustain operations. This constrains strategic choices, risks dilution, and makes long‑term execution dependent on financing availability.
Negative Equity And Stressed Balance SheetPersistently negative shareholders' equity signals cumulative losses and weak capital reserves. This limits access to conventional financing, raises creditor and covenant risk, and increases the probability of dilutive financings or onerous covenant concessions over the medium term.
Revenue Lumpiness And Milestone DependenceHeavy reliance on milestone payments, deferred recognition and one‑off partner receipts makes revenue volatile and forecasting difficult. For durable commercialization, predictable recurring revenues and reproducible sales cycles are required; current lumpiness raises execution and timing risk.
VolitionRX News
VNRX FAQ
What was VolitionRX’s price range in the past 12 months?
VolitionRX lowest stock price was $0.60 and its highest was $15.12 in the past 12 months.
What is VolitionRX’s market cap?
VolitionRX’s market cap is $8.05M.
When is VolitionRX’s upcoming earnings report date?
VolitionRX’s upcoming earnings report date is Nov 12, 2026 which is in 90 days.
How were VolitionRX’s earnings last quarter?
VolitionRX released its earnings results on Aug 13, 2026. The company reported -$0.85 earnings per share for the quarter, missing the consensus estimate of -$0.568 by -$0.282.
Is VolitionRX overvalued?
According to Wall Street analysts VolitionRX’s price is currently Undervalued.
Does VolitionRX pay dividends?
VolitionRX does not currently pay dividends.
What is VolitionRX’s EPS estimate?
VolitionRX’s EPS estimate is -0.43.
How many shares outstanding does VolitionRX have?
VolitionRX has 12,044,339 shares outstanding.
What happened to VolitionRX’s price movement after its last earnings report?
VolitionRX reported an EPS of -$0.85 in its last earnings report, missing expectations of -$0.568. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of VolitionRX?
Currently, no hedge funds are holding shares in VNRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
VolitionRX
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
VNRX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented substantial scientific and commercial progress across multiple product pillars (Nu.Q Vet automation and feline assay, Nu.Q NETs publications and point-of-care finger-prick breakthrough, Capture-Seq >99% pure ctDNA claims, Nu.Q Discover expansion), alongside improving headline revenue (+300% YoY) and a stronger quarter-end cash balance driven by financing and grants. However, important caveats include revenue lumpiness driven in part by deferred recognition, rising operating expenses and cash burn, reliance on milestone payments and external financing, and the need for broader validation, publications, and regulatory/reimbursement approvals to convert technical advances into predictable commercial revenue. On balance, the call signals strong technical momentum and growing commercial interest but with execution and timing risks to monetize those advances in the near term.View all VNRX earnings summariesVNRX Stock 12 Month Forecast
Average Price Target
$14.00
▲(1547.06% Upside)
Technical Analysis
Ownership Overview
9.74% Insiders
1.15% Mutual Funds
― Other Institutional Investors
88.47% Public Companies and
Individual Investors